This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

WASHINGTON (AP) — Pfizer says that its experimental COVID-19 pill appears effective against the omicron variant.

The company also confirmed Tuesday that the pill delivered on promising early results in reducing COVID-19 hospitalizations and deaths.

The updates come as U.S. regulators are expected to soon decide on whether to authorize Pfizer’s pill and a competing drug from Merck.

If authorized, the pills would be the first COVID-19 drugs that Americans could take at home to treat the virus.

Pfizer is seeking U.S. authorization for high-risk adults but is also studying the drug in lower-risk adults.

The company said the drug missed a key study goal in ongoing testing of those patients.